spliceostatin a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

spliceostatin A: antiangiogenic agent that blocks expression of VEGF; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	10673568
CHEMBL ID	1221942
SCHEMBL ID	18134895
MeSH ID	M0551984

Synonyms (11)

Synonym
CHEMBL1221942
[(z,2s)-4-[[(2r,3r,5s,6s)-6-[(2e,4e)-5-[(3r,4r,5r,7s)-4-hydroxy-7-methoxy-7-methyl-1,6-dioxaspiro[2.5]octan-5-yl]-3-methylpenta-2,4-dienyl]-2,5-dimethyloxan-3-yl]carbamoyl]but-3-en-2-yl] acetate
spliceostatin a
391611-36-2
SCHEMBL18134895
[(z,2s)-5-[[(2r,3r,5s,6s)-6-[(2e,4e)-5-[(3r,4r,5r,7s)-4-hydroxy-7-methoxy-7-methyl-1,6-dioxaspiro[2.5]octan-5-yl]-3-methylpenta-2,4-dienyl]-2,5-dimethyloxan-3-yl]amino]-5-oxopent-3-en-2-yl] acetate
Q59780090
BP-28004
HY-16466
CS-0006350
EX-A6219

Research Excerpts

Overview

Spliceostatin A (SSA) is a methylated derivative of an antitumor natural product FR901464, which specifically binds and inhibits the SF3b spliceosome sub-complex. It exhibits excellent anticancer activity against multiple human cancer cell lines.

Excerpt	Reference	Relevance
"Spliceostatin A is a potent inhibitor of spliceosomes and exhibits excellent anticancer activity against multiple human cancer cell lines. "	( Enantioselective Synthesis of a Cyclopropane Derivative of Spliceostatin A and Evaluation of Bioactivity. Ghosh, AK; Jurica, MS; Kovela, S; Prichard, BE; Reddy, GC; Relitti, N; Urabe, VK, 2018)	2.17
"Spliceostatin A (SSA) is a methyl ketal derivative of FR901464, a potent antitumor compound isolated from a culture broth of Pseudomonas sp no. "	( Global analysis of pre-mRNA subcellular localization following splicing inhibition by spliceostatin A. Burroughs, AM; Furuno, M; Hayashizaki, Y; Kaida, D; Kawamura, Y; Mayeda, A; Noma, S; Suzuki, H; Yoshida, M; Yoshimoto, R, 2017)	2.12
"Spliceostatin A (SSA) is a methylated derivative of an antitumor natural product FR901464, which specifically binds and inhibits the SF3b spliceosome sub-complex. "	( Spliceostatin A blocks angiogenesis by inhibiting global gene expression including VEGF. Furumai, R; Ishigami, K; Kojima, S; Komi, Y; Uchida, K; Watanabe, H; Yoneyama, M; Yoshida, M, 2010)	3.25
"Spliceostatin A (SSA) is a stabilized derivative of a Pseudomonas bacterial fermentation product that displays potent anti-proliferative and anti-tumor activities in cancer cells and animal models. "	( Reduced fidelity of branch point recognition and alternative splicing induced by the anti-tumor drug spliceostatin A. Corrionero, A; Miñana, B; Valcárcel, J, 2011)	2.03

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (28)

Assay ID	Title	Year	Journal	Article
AID503127	Binding affinity to SAP130 in human HeLa cells assessed as inhibition of beta-tubulin mRNA splicing at 100 ng/ml after 6 hrs by RT-PCR analysis	2007	Nature chemical biology, Sep, Volume: 3, Issue:9	Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA.
AID503124	Binding affinity to SAP130 assessed as inhibition of radio labeled IgM pre-mRNA splicing after 1 hr by autoradiography	2007	Nature chemical biology, Sep, Volume: 3, Issue:9	Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA.
AID1895047	Inhibition of pre-mRNA splicing in human HeLa nuclear extract in presence of ATP	2021	Journal of natural products, 05-28, Volume: 84, Issue:5	Spliceostatins and Derivatives: Chemical Syntheses and Biological Properties of Potent Splicing Inhibitors.
AID503134	Induction of intron translation of HA-tagged truncated p27 gene in HEK293T cells at 100 ng/ml for 14 hrs	2007	Nature chemical biology, Sep, Volume: 3, Issue:9	Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA.
AID1658701	Suppression of AR-V7 expression in human CWR22Rv1 cells expressing GFP measured after 3 days by FACS assay	2020	ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6	Design and Synthesis of 1,2-Deoxy-pyranose Derivatives of Spliceostatin A toward Prostate Cancer Treatment.
AID1658702	Toxicity in BALB/c mouse assessed as mouse death at 280 nM/body, iv measured after 24 hrs	2020	ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6	Design and Synthesis of 1,2-Deoxy-pyranose Derivatives of Spliceostatin A toward Prostate Cancer Treatment.
AID503123	Binding affinity to SAP130 assessed as inhibition of radio labeled beta-globin pre-mRNA splicing after 1 hr by autoradiography	2007	Nature chemical biology, Sep, Volume: 3, Issue:9	Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA.
AID503135	Induction of intron translation of Myc-tagged p27 gene in HEK293T cells at 100 ng/ml for 14 hrs by Western blotting	2007	Nature chemical biology, Sep, Volume: 3, Issue:9	Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA.
AID503152	Induction of CDK2 in HEK293T cells transfected with FLAG-tagged p27 at 190 nM by Western blot analysis	2007	Nature chemical biology, Sep, Volume: 3, Issue:9	Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA.
AID503155	Displacement of Ac-SSA from SF3b SAP155/SAP145/SAP130 complex in human HeLa cells by competition binding assay	2007	Nature chemical biology, Sep, Volume: 3, Issue:9	Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA.
AID503156	Displacement of biotinylated SSA from SF3b SAP155/SAP145/SAP130 complex in human HeLa cells by competition binding assay	2007	Nature chemical biology, Sep, Volume: 3, Issue:9	Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA.
AID503131	Binding affinity to SAP130 in human HeLa cells assessed as inhibition of IkappaBalpha pre-mRNA splicing between exon 1 and exon 4 at 10 mg/ml after 12 hrs by RT-PCR analysis	2007	Nature chemical biology, Sep, Volume: 3, Issue:9	Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA.
AID503133	Induction of subcellular localization of SC35 in human HeLa cells at 100 ng/ml after 3 hrs	2007	Nature chemical biology, Sep, Volume: 3, Issue:9	Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA.
AID503137	Induction of truncated p27 expression in SAP145-targeting siRNA-transfected human HeLa cells	2007	Nature chemical biology, Sep, Volume: 3, Issue:9	Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA.
AID503132	Induction of subcellular localization of poly(A) RNA in human HeLa cells at 100 ng/ml after 3 hrs using digoxigenin-labeled oligo-Dt probe	2007	Nature chemical biology, Sep, Volume: 3, Issue:9	Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA.
AID503120	Half life of the compound in culture medium by HPLC analysis	2007	Nature chemical biology, Sep, Volume: 3, Issue:9	Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA.
AID503105	Induction of beta-tubulin expression in human HeLa cells at 100 ng/ml after 14 hrs by Western blotting	2007	Nature chemical biology, Sep, Volume: 3, Issue:9	Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA.
AID503104	Induction of beta-actin expression in human HeLa cells at 100 ng/ml after 14 hrs by Western blotting	2007	Nature chemical biology, Sep, Volume: 3, Issue:9	Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA.
AID503138	Induction of truncated p27 expression in SAP130-targeting siRNA-transfected human HeLa cells	2007	Nature chemical biology, Sep, Volume: 3, Issue:9	Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA.
AID503130	Binding affinity to SAP130 in human HeLa cells assessed as inhibition of p27 pre-mRNA splicing between exon 1 and intron 2 at 10 mg/ml after 12 hrs by RT-PCR analysis	2007	Nature chemical biology, Sep, Volume: 3, Issue:9	Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA.
AID503126	Binding affinity to SAP130 in human HeLa cells assessed as inhibition of p27 mRNA splicing at 100 ng/ml after 6 hrs by RT-PCR analysis	2007	Nature chemical biology, Sep, Volume: 3, Issue:9	Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA.
AID503129	Binding affinity to SAP130 in human HeLa cells assessed as inhibition of p27 pre-mRNA splicing between exon 1 and exon 2 at 10 mg/ml after 12 hrs by RT-PCR analysis	2007	Nature chemical biology, Sep, Volume: 3, Issue:9	Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA.
AID503128	Binding affinity to SAP130 in human HeLa cells assessed as inhibition of beta-actin mRNA splicing at 100 ng/ml after 6 hrs by RT-PCR analysis	2007	Nature chemical biology, Sep, Volume: 3, Issue:9	Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA.
AID503139	Induction of subcellular localization of SAP155 in SAP155-targeting siRNA-transfected human HeLa cells after 3 days	2007	Nature chemical biology, Sep, Volume: 3, Issue:9	Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA.
AID503125	Binding affinity to SAP130 in human HeLa cells assessed as inhibition of FLAG-tagged beta globin splicing at 100 ng/ml after 12 hrs by RT-PCR analysis	2007	Nature chemical biology, Sep, Volume: 3, Issue:9	Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA.
AID503151	Induction of CDK2 in HEK293T cells transfected with FLAG-tagged truncated p27 at 190 nM by Western blot analysis	2007	Nature chemical biology, Sep, Volume: 3, Issue:9	Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA.
AID503136	Induction of truncated p27 expression in SAP155-targeting siRNA-transfected human HeLa cells	2007	Nature chemical biology, Sep, Volume: 3, Issue:9	Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA.
AID503140	Induction of subcellular localization of SAP145 in SAP145-targeting siRNA-transfected human HeLa cells after 3 days	2007	Nature chemical biology, Sep, Volume: 3, Issue:9	Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (42)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (2.38)	29.6817
2010's	33 (78.57)	24.3611
2020's	8 (19.05)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.47

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	27.47 (24.57)
Research Supply Index	3.76 (2.92)
Research Growth Index	5.54 (4.65)
Search Engine Demand Index	27.81 (26.88)
Search Engine Supply Index	2.00 (0.95)

This Compound (27.47)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	3 (7.14%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	39 (92.86%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
4,5,6,7-tetrabromo-2-azabenzimidazole 4,5,6,7-tetrabromobenzotriazole: a CK2 kinase inhibitor	2.06	1
cantharidin Cantharidin: A toxic compound, isolated from the Spanish fly or blistering beetle (Lytta (Cantharis) vesicatoria) and other insects. It is a potent and specific inhibitor of protein phosphatases 1 (PP1) and 2A (PP2A). This compound can produce severe skin inflammation, and is extremely toxic if ingested orally.. cantharidin : A monoterpenoid with an epoxy-bridged cyclic dicarboxylic anhydride structure secreted by many species of blister beetle, and most notably by the Spanish fly, Lytta vesicatoria. Natural toxin inhibitor of protein phosphatases 1 and 2A.	2.15	1	cyclic dicarboxylic anhydride; monoterpenoid	EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; herbicide
serine Serine: A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids.. serine : An alpha-amino acid that is alanine substituted at position 3 by a hydroxy group.	2.11	1	L-alpha-amino acid; proteinogenic amino acid; serine family amino acid; serine zwitterion; serine	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
propylene propylene: structure	2.1	1	alkene; gas molecular entity	refrigerant; xenobiotic
alkenes [no description available]	2.1	1
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	3.41	1	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
adenosine quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit	2.15	1	adenosines; purines D-ribonucleoside	analgesic; anti-arrhythmia drug; fundamental metabolite; human metabolite; vasodilator agent
triazoles Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.	2.06	1	1,2,3-triazole
trichostatin a trichostatin A: chelates zinc ion in the active site of histone deacetylases, resulting in preventing histone unpacking so DNA is less available for transcription; do not confuse with TRICHOSANTHIN which is a protein; found in STREPTOMYCES	2.03	1	antibiotic antifungal agent; hydroxamic acid; trichostatin	bacterial metabolite; EC 3.5.1.98 (histone deacetylase) inhibitor; geroprotector
herboxidiene herboxidiene: structure in first source; isolated from Streptomyces chromofuscus; a potent and selective herbicide (e.g. inactive against wheat); up-regulates the gene expression of LDL receptor	2.15	1
fr 901464 FR 901464: isolated from Pseudomonas; structure in first source	3.21	5
ci 940 leptomycin : A complex, very long chain, polyunsaturated fatty acid whose core structure comprises 8-oxononadeca-2,10,12,16,18-pentaenoic acid having methyl substituents at positions 3, 5, 7, 9, 11 and 15 and a 3,6-dihydropyran-6-one-2-yl group at position 19.	2.03	1	hydroxy polyunsaturated fatty acid; leptomycin	antifungal agent; bacterial metabolite
fr 901464 [no description available]	3.6	2	acetate ester; cyclic hemiketal; monocarboxylic acid amide; pyrans; spiro-epoxide	antimicrobial agent; antineoplastic agent; bacterial metabolite
monomethyl auristatin e [no description available]	3.41	1
meayamycin meayamycin: inhibits pre-mRNA splicing; has antineoplastic activity; structure in first source	3.41	1
oligonucleotides [no description available]	3.25	1
interleukin-8 Interleukin-8: A member of the CXC chemokine family that plays a role in the regulation of the acute inflammatory response. It is secreted by variety of cell types and induces CHEMOTAXIS of NEUTROPHILS and other inflammatory cells.	2.1	1
thailanstatin a [no description available]	3.41	1	C-glycosyl compound
thailanstatin b [no description available]	3.41	1
cyclin d1 Cyclin D1: Protein encoded by the bcl-1 gene which plays a critical role in regulating the cell cycle. Overexpression of cyclin D1 is the result of bcl-1 rearrangement, a t(11;14) translocation, and is implicated in various neoplasms.	3.25	1
pladienolide b pladienolide B: structure in first source	3.92	3

Condition	Relationship Strength	Studies
Cancer of Prostate [description not available]	2.6	1
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	2.6	1
Carcinogenesis The origin, production or development of cancer through genotypic and phenotypic changes which upset the normal balance between cell proliferation and cell death. Carcinogenesis generally requires a constellation of steps, which may occur quickly or over a period of many years.	3.06	1
Benign Neoplasms [description not available]	3.74	3
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	3.74	3
Cancer of Colon [description not available]	2.49	2
Colonic Neoplasms Tumors or cancer of the COLON.	2.49	2
Cytomegalovirus A genus of the family HERPESVIRIDAE, subfamily BETAHERPESVIRINAE, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions. Infection with Cytomegalovirus is also seen as an opportunistic infection in AIDS.	2.1	1
Genetic Predisposition [description not available]	2.11	1
Breast Cancer [description not available]	2.11	1
Carcinoma, Colloid [description not available]	2.11	1
Carcinoma, Papillary A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)	2.11	1
Breast Neoplasms Tumors or cancer of the human BREAST.	2.11	1
Adenocarcinoma, Mucinous An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)	2.11	1
B-Cell Chronic Lymphocytic Leukemia [description not available]	2.13	1
Leukemia, Lymphocytic, Chronic, B-Cell A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.	2.13	1
Dysmyelopoietic Syndromes [description not available]	3.06	1
Myelodysplastic Syndromes Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.	3.06	1
Angiogenesis, Pathologic [description not available]	2.05	1

chemdatabank.com